BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 22830956)

  • 1. The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries.
    Khunti K; Caputo S; Damci T; Dzida GJ; Ji Q; Kaiser M; Karnieli E; Liebl A; Ligthelm RJ; Nazeri A; Orozco-Beltran D; Pan C; Ross SA; Svendsen AL; Vora J; Yale JF; Meneghini LF;
    Diabetes Obes Metab; 2012 Dec; 14(12):1129-36. PubMed ID: 22830956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes.
    Meneghini L; Kesavadev J; Demissie M; Nazeri A; Hollander P
    Diabetes Obes Metab; 2013 Aug; 15(8):729-36. PubMed ID: 23421331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
    Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of insulin detemir once daily in combination with sitagliptin and metformin: the TRANSITION randomized controlled trial.
    Hollander P; Raslova K; Skjøth TV; Råstam J; Liutkus JF
    Diabetes Obes Metab; 2011 Mar; 13(3):268-75. PubMed ID: 21205123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and effectiveness of insulin analogues in type 2 diabetic patients from Algeria: a sub-analysis of the A₁chieve study.
    Malek R; Arbouche Z; Dahaoui A; Bachaoui M
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S15-26. PubMed ID: 23958568
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes.
    Fakhoury W; Lockhart I; Kotchie RW; Aagren M; LeReun C
    Pharmacology; 2008; 82(2):156-63. PubMed ID: 18679040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety of once- versus twice-daily insulin detemir added on to oral antidiabetics in insulin-naive type 2 diabetes patients: 24-week, crossover, treat to target trial in a single center.
    Cander S; Dizdar OS; Oz Gul O; Guclu M; Unal OK; Tuncel E; Erturk E; Imamoglu S; Ersoy C
    Prim Care Diabetes; 2014 Oct; 8(3):256-64. PubMed ID: 24522170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and effectiveness of insulin analogues in Moroccan patients with type 2 diabetes: a sub-analysis of the A₁chieve study.
    Chraibi A; Ajdi F; Belkhadir J; El Ansari N; Marouan F; Farouqi A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S27-36. PubMed ID: 23958569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin detemir versus insulin glargine for type 2 diabetes mellitus.
    Swinnen SG; Simon AC; Holleman F; Hoekstra JB; Devries JH
    Cochrane Database Syst Rev; 2011 Jul; 2011(7):CD006383. PubMed ID: 21735405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin analogues in children with Type 1 diabetes: a 52-week randomized clinical trial.
    Thalange N; Bereket A; Larsen J; Hiort LC; Peterkova V
    Diabet Med; 2013 Feb; 30(2):216-25. PubMed ID: 23094597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ; Scism-Bacon JL; Zagar AJ
    Diabetes Obes Metab; 2006 Jul; 8(4):448-55. PubMed ID: 16776752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J; Davies M; Home PD; Larsen J; Koenen C; Schernthaner G
    Diabetologia; 2008 Mar; 51(3):408-16. PubMed ID: 18204830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF; Dornhorst A; Sreenan S;
    Curr Med Res Opin; 2009 Apr; 25(4):1029-35. PubMed ID: 19281426
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight change upon once-daily initiation of insulin detemir with or without dietary intervention in overweight or obese insulin-naïve individuals with type 2 diabetes: results from the DIET trial.
    Niswender K; Piletic M; Andersen H; Conradsen Hiort L; Hollander P
    Diabetes Obes Metab; 2014 Feb; 16(2):186-92. PubMed ID: 24112375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of biphasic, basal-bolus or basal insulin analogue treatments on carotid intima-media thickness in patients with type 2 diabetes mellitus: the randomised Copenhagen Insulin and Metformin Therapy (CIMT) trial.
    Lundby-Christensen L; Vaag A; Tarnow L; Almdal TP; Lund SS; Wetterslev J; Gluud C; Boesgaard TW; Wiinberg N; Perrild H; Krarup T; Snorgaard O; Gade-Rasmussen B; Thorsteinsson B; Røder M; Mathiesen ER; Jensen T; Vestergaard H; Hedetoft C; Breum L; Duun E; Sneppen SB; Pedersen O; Hemmingsen B; Carstensen B; Madsbad S
    BMJ Open; 2016 Feb; 6(2):e008377. PubMed ID: 26916685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin lispro low mixture twice daily versus basal insulin glargine once daily and prandial insulin lispro once daily in patients with type 2 diabetes requiring insulin intensification: a randomized phase IV trial.
    Tinahones FJ; Gross JL; Onaca A; Cleall S; Rodríguez A
    Diabetes Obes Metab; 2014 Oct; 16(10):963-70. PubMed ID: 24725616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study.
    Meneghini LF; Rosenberg KH; Koenen C; Merilainen MJ; Lüddeke HJ
    Diabetes Obes Metab; 2007 May; 9(3):418-27. PubMed ID: 17391170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Once daily insulin detemir in patients with type 2 diabetes: results of German centers in a 6-month international observational study (SOLVE)].
    Liebl A; Wilhelm B; Kaiser M
    MMW Fortschr Med; 2012 Dec; 154 Suppl 4():102-9. PubMed ID: 23326928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring insulin analogue safety and effectiveness in a Maghrebian cohort with type 2 diabetes: results from the A₁chieve study.
    Belhadj M; Dahaoui A; Jamoussi H; Farouqi A
    Diabetes Res Clin Pract; 2013 Aug; 101 Suppl 1():S4-14. PubMed ID: 23958571
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.